Journal
NPJ PRECISION ONCOLOGY
Volume 5, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41698-021-00149-4
Keywords
-
Categories
Funding
- Ludwig Cancer Research
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP
Ask authors/readers for more resources
The FLAURA trial findings support osimertinib as the standard treatment for untreated patients with EGFR mutations, but resistance mechanisms like BRAF V600E may arise. This case highlights the potential efficacy of combining dabrafenib, trametinib, and osimertinib in later-line settings for patients with advanced EGFR-mutant lung adenocarcinoma.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E mutation arises as a unique mechanism of resistance, and thus far, no prospective studies are available to support concurrent EGFR/BRAF blockade. We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. Moreover, the patient experienced remarkable clinical improvement and good tolerance to combination therapy. The present case suggests the importance of prospective studies evaluating both efficacy and safety of the combination in later line settings and points towards the potential of ctDNA to monitor resistance mechanisms and treatment benefit in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available